ArticleVaccine2020
IgA as a potential candidate for enteric monoclonal antibody therapeutics with improved gastrointestinal stability.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Systematic Evaluation of Four Cysteine Proteases (Tropical medicine and infectious disease · 2026Article
- Short-term storage conditions do not affect canine fecal cortisol and secretory immunoglobulin A concentrations.Scientific reports · 2026Article
- Expression of porcine-derived IgA against PEDV and use of Alg-CS gel to protect the IgA from degradation in simulated gastric fluid.Archives of virology · 2025Article
- Polymeric immunoglobulin receptor (pIgR) in cancer progression: a critical role and potential therapeutic target.Apoptosis : an international journal on programmed cell death · 2025Review
- Review
- Intestinal immunoglobulins under microbial dysbiosis: implications in opioid-induced microbial dysbiosis.Frontiers in microbiology · 2025Review
- Stability Engineering of Recombinant Secretory IgA.International journal of molecular sciences · 2024Article
- Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract.Science advances · 2024Article
- Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance.International journal of molecular sciences · 2024Review
- Combinatorially restricted computational design of protein-protein interfaces to produce IgG heterodimers.Science advances · 2024Article
- The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections.Human vaccines & immunotherapeutics · 2022Review
- How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.Journal of nanobiotechnology · 2021Review
- The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.International journal of molecular sciences · 2021Review
- Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.International journal of molecular sciences · 2021Review
- Human genital antibody-mediated inhibition of Chlamydia trachomatis infection and evidence for ompA genotype-specific neutralization.PloS one · 2021Article
- Antibody-Mediated Targeting of Antigens to Intestinal Aminopeptidase N Elicits Gut IgA Responses in Pigs.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal surfaces of the gastrointestinal tract play an important role in immune homeostasis and defense and may be compromised by enteric disorders or infection. Therapeutic intervention using monoclonal antibody (mAb) offers the potential for treatment with minimal off-target effects as well as the possibility of limited systemic exposure when administered orally. Critically, to achieve efficacy at luminal surfaces, mAb must remain stable and functionally active in the gastrointestinal environment. To better understand the impact of isotype, class, and molecular structure on the intestinal stability of recombinant antibodies, we used an in vitro simulated intestinal fluid (SIF) assay to evaluate a panel of antibody candidates for enteric mAb-based therapeutics. Recombinant IgG1 was the least stable following SIF incubation, while the stability of IgA generally increased upon polymerization, with subtle differences between subclasses. Notably, patterns of variability within and between mAbs suggest that variable regions contribute to mAb stability and potentially mediate mAb susceptibility to proteases. Despite relatively rapid degradation in SIF, mAbs targeting Enterotoxigenic Escherichia coli (ETEC) displayed functional activity following SIF treatment, with SIgA1 showing improved function compared to SIgA2. The results of this study have implications for the design of enteric therapeutics and subsequent selection of lead candidates based upon in vitro intestinal stability assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.